Institut Gustave Roussy

Site:	Institut Gustave Roussy			Go to their website
Address:
City:	Villejuif
State:	Val de Narne
Zip:	94805
Country:	France

35 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [asc]	NCT#
2	A phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib	Unknown	Closed	Masitinib, (AB1010)	NCT01506336
1	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers	Completed	Closed	Masitinib, (AB1010)
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
1	A Study of NB003 in Patients With Advanced Malignancies	Recruiting	Active	NB003	NCT04936178
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
2	Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)	Ongoing, but not recruiting	Closed	Palbociclib	NCT01907607
2	Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)	Completed	Closed	Pazopanib (Votrient)	NCT01323400
1/2	Phase I/II Study of PDR001 in Patients With Advanced Malignancies	Active, not recruiting	Closed	PDR001	NCT02404441
2	Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)	Active, not recruiting	Not yet activated	Pembrolizumab + Cyclophosphamide	NCT02406781
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	A Study of R1507 in Patients With Recurrent or Refractory Sarcoma	Does not allow GIST	Closed	R1507	NCT00642941
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)	Completed	Active	Regorafenib (SDH)	NCT02638766
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105